Lupin Launches Dasatinib Tablets in the United States

Kiran DSIJCategories: Mindshare, Trendingjoin us on whatsappfollow us on googleprefered on google

Lupin Launches Dasatinib Tablets in the United States

Lupin is committed to improving patient health outcomes through its subsidiaries - Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions.

Lupin Limited has officially launched its generic version of Dasatinib Tablets in the United States, following a successful Abbreviated New Drug Application (ANDA) approval from the U.S. FDA. Developed in partnership with Pharmascience Inc., these tablets are available in multiple strengths ranging from 20 mg to 140 mg. As a bioequivalent alternative to Bristol-Myers Squibb’s Sprycel®, this launch targets a significant market segment, with the brand-name drug seeing estimated annual U.S. sales of approximately $930 million as of late 2025.

The newly introduced medication is indicated for a broad range of patients, specifically those battling Philadelphia chromosome-positive (Ph+) conditions. This includes adults with newly diagnosed chronic myeloid leukaemia (CML) or those who have shown resistance to prior therapies like imatinib. Furthermore, the treatment extends to paediatric patients aged one year and older for both chronic phase CML and newly diagnosed acute lymphoblastic leukaemia (ALL) when used in combination with chemotherapy. This expansion into the U.S. market underscores Lupin's commitment to providing accessible oncology treatments for complex chronic conditions.

Invest where stability meets growth. DSIJ’s Mid Bridge reveals Mid-Cap leaders ready to outperform. Download Detailed Note Here

About Lupin

Lupin Ltd is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. Lupin specialises in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position in India and the U.S. across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women's health. Lupin has 15 state-of-the-art manufacturing sites and 7 research centres globally, along with a dedicated workforce of over 24,000 professionals. Lupin is committed to improving patient health outcomes through its subsidiaries - Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions.

Disclaimer: The article is for informational purposes only and not investment advice.